Survival and safety of treatment with infliximab in the elderly population.
Chevillotte-Maillard
H
H
Ornetti
P
P
Mistrih
R
R
Sidot
C
C
Dupuis
J
J
Dellas
J-A
JA
Tavernier
C
C
Maillefert
J F
JF
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000009:adverse effects; D047889:Receptors, Tumor Necrosis Factor, Type II; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D053319:Tumor Necrosis Factor Decoy Receptors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D000069285:Infliximab